Special ArticleSpecial Article: Translational Science Update. Pharmacological Implications of Emerging Schizophrenia Genetics Can the Bridge From ‘Genomics’ to ‘Therapeutics’ be Defined and Traversed?Birnbaum, Rebecca MD∗; Weinberger, Daniel R. MD†Author Information From the ∗Icahn School of Medicine at Mount Sinai, Departments of Psychiatry, Genetics and Genomic Sciences, New York, NY †Lieber Institute for Brain Development and the Departments of Psychiatry, Neurology, Neuroscience and Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Reprints: Daniel R. Weinberger, MD, Lieber Institute for Brain Development, and the Departments of Psychiatry, Neurology, Neuroscience and Genetic Medicine, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, MD 21205 (e-mail: email@example.com). Journal of Clinical Psychopharmacology: 7/8 2020 - Volume 40 - Issue 4 - p 323-329 doi: 10.1097/JCP.0000000000001215 Buy Metrics Abstract Recent schizophrenia genome-wide association studies (GWAS) have identified genomic variants of common and rare frequency, significantly associated with schizophrenia. While numerous functional genomics efforts are ongoing to elucidate the biological effects of schizophrenia risk variants, a consideration of their therapeutic implications is timely and imperative, for patients as well as for an iterative effect on elucidating the underlying biology and pathophysiology of illness. The current article reviews efforts to translate emerging schizophrenia genomics into novel approaches to target discovery and therapeutic intervention. Though the path from ‘genetic risk to therapy’ is far from straightforward, there are provocative early possibilities that harbor the promise of treatment based on causation rather than phenomenology, as well as ‘precision psychiatry,’ a basis for stratifying patients to enable more precise and effective, personalized therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.